167 related articles for article (PubMed ID: 9126748)
1. Application of a new anticoagulant (Nafamostat Mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation--a preliminary report.
Nagaya M; Futamura M; Kato J; Niimi N; Fukuta S
J Pediatr Surg; 1997 Apr; 32(4):531-5. PubMed ID: 9126748
[TBL] [Abstract][Full Text] [Related]
2. Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation.
Park JH; Her C; Min HK; Kim DK; Park SH; Jang HJ
Int J Artif Organs; 2015 Nov; 38(11):595-9. PubMed ID: 26728787
[TBL] [Abstract][Full Text] [Related]
3. Anticoagulation During Extracorporeal Membrane Oxygenation; Nafamostat Mesilate Versus Heparin.
Lim JY; Kim JB; Choo SJ; Chung CH; Lee JW; Jung SH
Ann Thorac Surg; 2016 Aug; 102(2):534-9. PubMed ID: 27083248
[TBL] [Abstract][Full Text] [Related]
4. Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation.
Han SJ; Kim HS; Kim KI; Whang SM; Hong KS; Lee WK; Lee SH
J Korean Med Sci; 2011 Jul; 26(7):945-50. PubMed ID: 21738350
[TBL] [Abstract][Full Text] [Related]
5. [Beneficial characteristics of protease inhibitor as an anticoagulant for extracorporeal circulation].
Akizawa T
Rinsho Ketsueki; 1990 Jun; 31(6):782-6. PubMed ID: 2214168
[TBL] [Abstract][Full Text] [Related]
6. Comparative clinical trial of regional anticoagulation for hemodialysis.
Akizawa T; Kitaoka T; Sato M; Koshikawa S; Hirasawa Y; Kazama M; Mimura N; Ota K
ASAIO Trans; 1988; 34(3):176-8. PubMed ID: 3058171
[TBL] [Abstract][Full Text] [Related]
7. Nafamostat mesilate reduces blood loss during open heart surgery.
Murase M; Usui A; Tomita Y; Maeda M; Koyama T; Abe T
Circulation; 1993 Nov; 88(5 Pt 2):II432-6. PubMed ID: 8222190
[TBL] [Abstract][Full Text] [Related]
8. Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding.
Akizawa T; Koshikawa S; Ota K; Kazama M; Mimura N; Hirasawa Y
Nephron; 1993; 64(3):376-81. PubMed ID: 8341382
[TBL] [Abstract][Full Text] [Related]
9. Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk.
Matsuo T; Kario K; Nakao K; Yamada T; Matsuo M
Haemostasis; 1993; 23(3):135-41. PubMed ID: 8276316
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of nafamstat mesilate (FUT 175). A new anticoagulant for plasmapheresis.
Hosokawa S; Oyamaguchi A; Yoshida O
ASAIO J; 1992; 38(1):59-60. PubMed ID: 1554918
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a pharmacy managed heparin protocol for extracorporeal membrane oxygenation patients.
Fitousis K; Klasek R; Mason PE; Masud F
Perfusion; 2017 Apr; 32(3):238-244. PubMed ID: 27837164
[TBL] [Abstract][Full Text] [Related]
12. Coagulation and anticoagulation in extracorporeal membrane oxygenation.
Muntean W
Artif Organs; 1999 Nov; 23(11):979-83. PubMed ID: 10564301
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation].
Tsukagoshi S
Gan To Kagaku Ryoho; 2000 May; 27(5):767-74. PubMed ID: 10832450
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulation and pediatric extracorporeal membrane oxygenation: impact of activated clotting time and heparin dose on survival.
Baird CW; Zurakowski D; Robinson B; Gandhi S; Burdis-Koch L; Tamblyn J; Munoz R; Fortich K; Pigula FA
Ann Thorac Surg; 2007 Mar; 83(3):912-9; discussion 919-20. PubMed ID: 17307433
[TBL] [Abstract][Full Text] [Related]
15. [Effectiveness of FUT-175, protease inhibitor, as an anticoagulant to hemodialysis].
Pak K; Shirasu A; Okino K; Sako H; Nakane Y; Umemura K; Maeda S; Tomoyoshi T
Hinyokika Kiyo; 1988 Jun; 34(6):1077-81. PubMed ID: 3223453
[TBL] [Abstract][Full Text] [Related]
16. [Experimental study on heparin-free cardiopulmonary bypass using nafamostat mesilate (FUT-175) and heparin-coated circuit].
Takano H; Miyamoto Y; Kaneko M; Matsuwaka R; Kuratani T; Amemiya A; Nakano S; Matsuda H
Nihon Kyobu Geka Gakkai Zasshi; 1993 Nov; 41(11):2166-73. PubMed ID: 8283086
[TBL] [Abstract][Full Text] [Related]
17. A comparison of low and standard anti-coagulation regimens in extracorporeal membrane oxygenation.
Raman J; Alimohamed M; Dobrilovic N; Lateef O; Aziz S
J Heart Lung Transplant; 2019 Apr; 38(4):433-439. PubMed ID: 30744940
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of nafamostat mesilate as a regional anticoagulant in experimental direct hemoperfusion and in plasma exchange on humans.
Abe H; Tani T; Numa K; Endo Y; Yoshioka T; Kodama M
Artif Organs; 1992 Apr; 16(2):206-8. PubMed ID: 10078246
[TBL] [Abstract][Full Text] [Related]
19. Plasma collection using nafamostat mesilate and dipyridamole as an anticoagulant.
Hiraishi M; Yamazaki Z; Ichikawa K; Kanai F; Idezuki Y; Onishi K; Takahama T; Inoue N
Int J Artif Organs; 1988 May; 11(3):212-6. PubMed ID: 3403059
[TBL] [Abstract][Full Text] [Related]
20. Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients.
Krueger K; Schmutz A; Zieger B; Kalbhenn J
Artif Organs; 2017 Feb; 41(2):186-192. PubMed ID: 27256966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
